199 related articles for article (PubMed ID: 35747976)
1. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).
Wang K; Zhang K; Zhang X; Chen D; Jiang S
Mini Rev Med Chem; 2023; 23(11):1154-1166. PubMed ID: 35747976
[TBL] [Abstract][Full Text] [Related]
2. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
3. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Tian Y; Tang B; Wang C; Sun D; Zhang R; Luo N; Han Z; Liang R; Gao Z; Wang L
Oncotarget; 2016 Jul; 7(29):46230-46241. PubMed ID: 27323827
[TBL] [Abstract][Full Text] [Related]
4. Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway.
Zhao C; Zheng L; Ma Y; Zhang Y; Yue C; Gu F; Niu G; Chen Y
Int J Immunopathol Pharmacol; 2024; 38():3946320241249445. PubMed ID: 38679570
[TBL] [Abstract][Full Text] [Related]
5. ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin.
Chen B; Cha JH; Yan M; Cao N; Ye P; Yan X; Yang WH
Biochem Biophys Res Commun; 2021 Oct; 573():1-8. PubMed ID: 34375763
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Harris K; Smith L
Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
[TBL] [Abstract][Full Text] [Related]
8. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
Das BK; Choukimath SM; Gadad PC
Life Sci; 2019 Aug; 230():10-18. PubMed ID: 31121175
[TBL] [Abstract][Full Text] [Related]
9. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Schulte L; Scheiner B; Voigtländer T; Koch S; Schweitzer N; Marhenke S; Ivanyi P; Manns MP; Rodt T; Hinrichs JB; Weinmann A; Pinter M; Vogel A; Kirstein MM
Liver Int; 2019 Apr; 39(4):714-726. PubMed ID: 30663219
[TBL] [Abstract][Full Text] [Related]
10. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.
Saito T; Chiba T; Yuki K; Zen Y; Oshima M; Koide S; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Tada M; Kanai F; Takiguchi Y; Iwama A; Yokosuka O
PLoS One; 2013; 8(7):e70010. PubMed ID: 23922888
[TBL] [Abstract][Full Text] [Related]
11. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27
Tuo L; Xiang J; Pan X; Hu J; Tang H; Liang L; Xia J; Hu Y; Zhang W; Huang A; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Feb; 38(1):50. PubMed ID: 30717766
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application.
Abdelhamid AM; Saber S; Youssef ME; Gaafar AGA; Eissa H; Abd-Eldayem MA; Alqarni M; Batiha GE; Obaidullah AJ; Shahien MA; El-Ahwany E; Amin NA; Etman MA; Kaddah MMY; Abd El-Fattah EE
Biomed Pharmacother; 2022 Jan; 145():112455. PubMed ID: 34844106
[TBL] [Abstract][Full Text] [Related]
14. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
Chen HP; Shieh JJ; Chang CC; Chen TT; Lin JT; Wu MS; Lin JH; Wu CY
Gut; 2013 Apr; 62(4):606-15. PubMed ID: 22773548
[TBL] [Abstract][Full Text] [Related]
15. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway.
Yi G; He Z; Zhou X; Xian L; Yuan T; Jia X; Hong J; He L; Liu J
Int J Oncol; 2013 Nov; 43(5):1503-10. PubMed ID: 23982736
[TBL] [Abstract][Full Text] [Related]
16. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
17. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A; Marisi G; Scarpi E; Scartozzi M; Faloppi L; Silvestris N; Masi G; Vivaldi C; Brunetti O; Tamberi S; Foschi FG; Tamburini E; Tenti E; Ricca Rosellini S; Ulivi P; Cascinu S; Nanni O; Frassineti GL
Expert Opin Pharmacother; 2015; 16(18):2719-25. PubMed ID: 26513009
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway.
Xiong Y; Lu QJ; Zhao J; Wu GY
Asian Pac J Cancer Prev; 2012; 13(7):3275-9. PubMed ID: 22994747
[TBL] [Abstract][Full Text] [Related]
19. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of Sirtuin 1 by AMP-activated protein kinase promotes metformin-induced senescence in hepatocellular carcinoma xenografts.
Zhou X; Chen J; Chen L; Feng X; Liu Z; Hu L; Zeng Z; Jia X; Liang M; Shi B; Yi G; Liu J
Cancer Lett; 2017 Dec; 411():1-11. PubMed ID: 28964787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
